Oral semaglutide, however, is a large molecule that is difficult for the stomach to absorb
Understanding this connection is important for anyone taking Semaglutide or considering it as part of their treatment plan
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
The story of Semaglutides journey begins with the discovery of glucagon-like peptide-1 (GLP-1), a hormone produced in the intestine that plays a crucial role in regulating blood sugar levels
L., Khalid, U., O'Neil, P
